Skip to content

Comparison of AuraGain With I-gel for Pediatric Patients

A Randomized Trial of Ambu® AuraGain™ Versus I-gel® in Young Children

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03294226
Enrollment
68
Registered
2017-09-26
Start date
2017-09-25
Completion date
2018-03-24
Last updated
2018-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthesia

Brief summary

Children from 6 months to 6 years are randomly allocated into AuraGain group or I-gel group. After anesthetic induction without neuromuscular blocking agent, assigned device in inserted by skillful anesthesiologist. The outcome measures are recorded and analysed.

Interventions

DEVICEAuraGain

After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.

DEVICEI-gel

After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.

Sponsors

Asan Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
6 Months to 6 Years
Healthy volunteers
No

Inclusion criteria

* ASA physical status: 1-3 * age: from 6 months to 6 year * body weight: 5-20kg * patients undergoing upper/lower extremity surgery at supine position

Exclusion criteria

* patients who do not want to participate in this study * patients with known difficult airway including congenital facial anomaly or history of difficult airway management * patients with aspiration risk (gastrointestinal stenosis or stricture) * patients with symptom of upper respiratory infection on the day of surgery * patients scheduled for day surgery * patients judged as not eligible by researchers for other reasons

Design outcomes

Primary

MeasureTime frameDescription
requirement of additional airway maneuverduring placement/maintenance of the deviceincluding adjustment of head/neck position or insertion depth and taping of the device

Secondary

MeasureTime frameDescription
success rateduring placement of the device
ease of gastric tube insertionwithin 10 minutes after device insertion
adverse effect at operating roomduring anesthesiaaspiration of gastric fluid, hypoxia, SpO2\<90%, bronchospasm, dental/tongue/lip trauma, staining of blood on the removed device
insertion timeduring placement of the device
fiberoptic view of glottiswithin 10 minutes after device insertionBrimacombe score
oropharyngeal leak pressureat 1 minute after device insertion, at 10 minutes after device insertion
postoperative adverse effectwithin postoperative 24 hourssore throat, hoarseness, airway obstruction

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026